Rezolute Inc SEC Filings

Rezolute, Inc. (RZLT) reported an insider equity grant for director Gil M. Labrucherie. On 11/19/2025, he received 21,000 restricted stock units at a price of $0, which fully vest on December 1, 2026. Following this grant, he beneficially owns 55,500 common shares directly and 53,572 common shares indirectly through The Labrucherie Trust dated 9/1/2009.

He was also granted a director stock option for 12,000 common shares at an exercise price of $10.16 per share on 11/19/2025. These options are exercisable until 11/19/2035 and fully vest on December 1, 2026.

Rezolute, Inc. filed an 8-K noting it hosted an investor event and related presentation to provide an update on the Ersodetug development program.

The presentation is furnished as Exhibit 99.1 and is not deemed “filed” under the Exchange Act. The company included customary forward‑looking statements cautions and referred readers to its risk factors in prior SEC filings. Rezolute’s common stock trades on the Nasdaq Capital Market under the symbol RZLT.

Rezolute, Inc. (RZLT) filed its quarterly report, highlighting continued late-stage development of ersodetug and typical clinical-stage losses. The company reported a net loss of $18.2 million for the quarter on operating expenses of $19.8 million. Interest and other income was $1.7 million.

Liquidity remains strong with cash and cash equivalents of $9.1 million and investments in marketable debt securities of $143.1 million as of September 30, 2025. Total assets were $158.7 million and shareholders’ equity was $147.2 million. Management believes existing cash and investments will fund operations for at least 12 months.

Key pipeline updates include the Phase 3 sunRIZE study in congenital hyperinsulinism with topline data anticipated in December 2025, and FDA-agreed modifications to the Phase 3 upLIFT trial in tumor hyperinsulinism to a single-arm, open-label design in as few as 16 participants. Capital actions included an April 2025 underwritten offering with approximately $103.5 million gross proceeds and termination of a $50.0 million at-the-market program in October 2025. As of November 4, 2025, 92,727,532 common shares were outstanding.

Rezolute, Inc. (RZLT) furnished an 8‑K announcing it issued a press release with financial results for the first quarter ended September 30, 2025. The press release is provided as Exhibit 99.1.

The information, including Exhibit 99.1, is being furnished and is not deemed “filed” under the Exchange Act. Rezolute’s common stock trades on the Nasdaq Capital Market under the symbol RZLT.

Rezolute, Inc. reported two corporate actions. The company amended employment agreements for its CEO Nevan C. Elam, CMO Brian Roberts, CFO Daron Evans, and CCO Sunil Karnawat to provide a full gross-up payment for any excise tax and related taxes arising from “excess parachute payments” in a change of control under Section 280G. The company will determine the gross-up amount in its sole discretion, and the amendments will be filed with the next Form 10-Q.

Rezolute also delivered written notice to terminate its Open Market Sale Agreement with Jefferies LLC, effective October 24, 2025. The agreement supported an at-the-market program established under a November 2023 S-3 shelf. The company states it did not undertake any sales under the at-the-market program.

Rezolute, Inc. is asking shareholders to vote at the Annual Meeting on a slate of routine corporate matters including election of seven director nominees, ratification of Grant Thornton LLP as independent auditor, a non-binding advisory vote on executive compensation, and an amendment to the 2021 Equity Incentive Compensation Plan to increase available shares from 14,450,000 to 21,950,000. The proxy materials will be delivered primarily via internet starting on or about October 10, 2025 to stockholders of record as of the September 22, 2025 record date. The 2021 Equity Plan summary states the plan covers a variety of award types including options, SARs, restricted stock, RSUs, dividend equivalents and other stock-based awards and describes standard change-in-control and replacement provisions. The company discloses a Clawback Policy that permits recovery of incentive compensation for up to three years prior to a required financial restatement and states the Compensation Committee administers that policy and the 2021 Equity Plan.

Rezolute, Inc. Schedule 13G summary: This filing reports that several affiliated entities and individuals associated with Invus and Avicenna disclosed beneficial ownership of Rezolute common stock. Invus Public Equities directly holds 4,171,401 shares (about 4.6% of the class) and Avicenna Life Sci Master Fund LP directly holds 698,599 shares (about 0.8%). Combined, Mr. Raymond Debbane is disclosed as beneficial owner of 4,870,000 shares, representing 5.4% of the 90,811,368 shares outstanding used in the calculation. The filing states the positions were not acquired to change control of the issuer and lists addresses and organizational citizenship for each reporting person.

Rezolute, Inc. reported material financing and corporate items in its Form 10-K. The company completed an underwritten offering in April 2025 that generated aggregate gross proceeds of approximately $103.5 million and net proceeds of approximately $96.8 million. During fiscal 2025 the company also completed private placements that yielded net proceeds of $4.2 million and $6.0 million in prior periods, and issued pre-funded warrants and common stock in multiple transactions.

The filing discloses license and milestone obligations, including a $5.0 million milestone paid in May 2025 under the XOMA License Agreement upon dosing in a Phase 3 trial, a $25.0 million milestone due upon regulatory approval and up to $185.0 million of additional milestone payments tied to annual net sales. The company reports significant net operating loss (NOL) carryforwards totaling approximately $201.4 million with portions subject to expiration and IRC Section 382 limitations.